Advances in Study on Three-dimensional Printing in Pharmaceutics

Three dimensional printing（3DP） is a solid freeform fabrication technology which employs powder processing and a liquid binder material in the construction of parts in a layer-wise manner. 3DP can accommodate much geometric outline and be made with many materials due to its unprecedented flexibility. The technology can control over the material composition, microstructure and surface texture so it attracts great attentions in the pharmaceutics field. 3DP can offer many novel strategies and approaches for the research and is widely focused in the field of the controlled-release drug delivery systems. Through consulting a large number of documents the current development and the technical characteristics of 3DP in pharmaceutics field are discussed and reviewed. It is expected that 3DP technique may play a tremendous role in pharmaceutics field in the future.Three dimensional printing （3DP） is a solid freeform fabrication technology which employs powder processing and a liquid binder material in the construction of parts in a layer-wise manner. 3DP can accommodate much geometric outline and be made with many materials due to its unprecedented flexibility. The technology can control over the material composition, microstructure and surface texture so it attracts great attentions in the pharmaceutics field. 3DP can offer many novel strategies and approaches for the research and is widely focused in the field of the controlled-release drug delivery systems. Through consulting a large number of documents the current development and the technical characteristics of 3DP in pharmaceutics field are discussed and reviewed. It is expected that 3DP technique may play a tremendous role in pharmaceutics field in the future.

Modeling solubility of oxaprozin and irbesartan in biorelevant complex solutions based on a combination of pH-dependent and micellar solubilization models

Biological solubility is one of the important basic parameters in the development process of poorly soluble drugs,but the current measurement methods are mainly based on a large number of experiments,which are time-consuming and cost-intensive.There is still a lack of effective theoretical models to accurately describe and predict the biological solubility of drugs to reduce costs.Therefore,in this study,osaprazole and irbesartan were selected as model drugs,and their solubility in solutions containing surfactants and biorelevant media was measured experimentally.By calculating the parameters of each component using the perturbed-chain statistical associating fluid theory(PC-SAFT)model,combined with pH-dependent and micellar solubilization models,the thermodynamic phase behavior of the two drugs was successfully modeled,and the predicted results were in good agreement with the experimental values.These results demonstrate that the model combination used provides important basic parameters and theoretical guidance for the development and screening of poorly soluble drugs and related formulations.

Potentials of ribosomopathy gene as pharmaceutical targets for cancer treatment

Ribosomopathies encompass a spectrum of disorders arising from impaired ribosome biogenesis and reduced functionality.Mutation or dysexpression of the genes that disturb any finely regulated steps of ribosome biogenesis can result in different types of ribosomopathies in clinic,collectively known as ribosomopathy genes.Emerging data suggest that ribosomopathy patients exhibit a significantly heightened susceptibility to cancer.Abnormal ribosome biogenesis and dysregulation of some ribosomopathy genes have also been found to be intimately associated with cancer development.The correlation between ribosome biogenesis or ribosomopathy and the development of malignancies has been well established.This work aims to review the recent advances in the research of ribosomopathy genes among human cancers and meanwhile,to excavate the potential role of these genes,which have not or rarely been reported in cancer,in the disease development across cancers.We plan to establish a theoretical framework between the ribosomopathy gene and cancer development,to further facilitate the potential of these genes as diagnostic biomarker as well as pharmaceutical targets for cancer treatment.

Evaluation of Phytochemical Contents and Antimicrobial Activities of Pandiaka heudelotii

The work investigated the secondary metabolites present in different parts of the Pandiaka heudelotii plant harvested from Ezira, Orumba south local government area of Anambra state, southeastern Nigeria as well as their antimicrobial activity. The objectives were to extract, determine the phytochemicals present, evaluate the antimicrobial potential and determine the zones of inhibition of the root, stem and leaf extracts of the plant. The emergence of antibiotics has decreased the spread and severity of a wide range of diseases. Plant extracts were tested for antibacterial and antifungal activities against Staphylococcus aureus, Escherichia coli, Proteus vulgaris, Streptococcus pyogenes, Bacillus subtelis, Pseudomonas aerogenes, Salmonella typhi, Aspergillus flavus, Aspergillus niger and Candida albicans. The zone of inhibition of extracts was compared with that of standard drugs like Erythromycin, Ciprofloxacin, Fulcin and Fluconazole. The result revealed the inhibition of bacterial and fungal growth with some test organisms. The microbial activity of the plant parts may be due to the presence of various secondary metabolites. The ethyl acetate extracts of Pandiaka heudelotii stood out with a minimum inhibitory concentration (MIC) range of 5 - 10 mg/mL and a minimum bactericidal concentration (MBC)/minimum fungicidal concentration (MFC) of 10 - 20 mg/ml against some test organisms. The plant can thus be worked upon to discover biologically active natural products that may serve as a prelude to the development of new pharmaceutical research undertakings.

Digital Transformation Trend of the Pharmaceutical Distribution Industry in the Context of New Infrastructure in China

Objective To study the pharmaceutical distribution industry against the background of new infrastructure construction since it is vital to the health and life of the public,and to offer some suggestions to further improve the industry quality and achieve industry upgrading.Methods The national strategies for new infrastructure as well as the underlying logic for enterprise digital transformation were analyzed to provide the outlook on the digital transformation trend of the pharmaceutical distribution industry.Results and Conclusion In the future,the pharmaceutical distribution industry shall transform the pattern,channel,management and control,and experience in the entire business chain in a digital way by focusing on connection efficiency,data efficiency and decision-making efficiency.

Research on the Improvement of Incentive Mechanism for Pharmaceutical Sales Personnel - Taking Company A as an Example

Objective To analyze the improvement of the incentive mechanism of sales personnel in pharmaceutical company A,and to promote the smooth operation and further development of the company in a long term.Methods Compensation incentive,performance appraisal,welfare benefit,training incentive,promotion motivation and enterprise cultural inspiration were explored through questionnaires,telephone interviews and in-person interviews.Results and Conclusion This company’s incentive mechanism has problems in two aspects:Material incentives and spiritual incentives.As to the company’s characteristics and strategic development,the optimization countermeasures of incentive mechanism are proposed from the following three aspects:constructing a reasonable incentive system,establishing an efficient spiritual incentive mechanism,and implementing the dynamic incentive and differentiated incentive simultaneously.

Research on the Threshold Effect of China’s Pharmaceutical Export Trade on Internal and External R&D Investment

Objective To study the threshold effect of export trade on internal and external R&D investment in China’s pharmaceutical industry,and to provide reference for some pharmaceutical enterprises to improve the investment.Methods The panel data of pharmaceutical industry in 25 provinces and cities in China from 2009 to 2019 were selected to conduct empirical analysis by establishing a threshold regression model,and a better export trade interval was obtained.Results and Conclusion There is a threshold value for the effect of new product export on both internal and external R&D expenditures,and the threshold values are 845.2788 million yuan and 318.4198 million yuan,respectively.There is a single threshold effect of export trade on both internal and external R&D investment in China’s pharmaceutical industry,and the effect of export trade on internal and external R&D investment changes from negative to positive as the export trade develops from low to high.

A Framework for Cloud Validation in Pharma

The pharmaceutical industry’s increasing adoption of cloud-based technologies has introduced new challenges in computerized systems validation (CSV). This paper explores the evolving landscape of cloud validation in pharmaceutical manufacturing, focusing on ensuring data integrity and regulatory compliance in the digital era. We examine the unique characteristics of cloud-based systems and their implications for traditional validation approaches. A comprehensive review of current regulatory frameworks, including FDA and EMA guidelines, provides context for discussing cloud-specific validation challenges. The paper introduces a risk-based approach to cloud CSV, detailing methodologies for assessing and mitigating risks associated with cloud adoption in pharmaceutical environments. Key considerations for maintaining data integrity in cloud systems are analyzed, particularly when applying ALCOA+ principles in distributed computing environments. The article presents strategies for adapting traditional Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) models to cloud-based systems, highlighting the importance of continuous validation in dynamic cloud environments. The paper also explores emerging trends, including integrating artificial intelligence and edge computing in pharmaceutical manufacturing and their implications for future validation strategies. This research contributes to the evolving body of knowledge on cloud validation in pharmaceuticals by proposing a framework that balances regulatory compliance with the agility offered by cloud technologies. The findings suggest that while cloud adoption presents unique challenges, a well-structured, risk-based approach to validation can ensure the integrity and compliance of cloud-based systems in pharmaceutical manufacturing.

Countermeasures and Suggestions for Strengthening Human Resource Management in China’s Pharmaceutical Industry

Objective To provide reference and enlightenment for the development of human resource management in China’s pharmaceutical industry and to put forward some suggestions to promote the further development of pharmaceutical industry.Methods The method of literature review was used to analyze the current situation and existing problems of human resource management in China’s pharmaceutical industry.Results and Conclusion Only by continuously improving the human resource management skills and innovating management methods can pharmaceutical enterprises achieve long-term benefits with sustainable development.The formulation of human resource management strategy in pharmaceutical industry must be conducive to the realization of the business goals of enterprises.To achieve this overall goal,the human resources management department of enterprises must make the plan from a strategic perspective,formulate talent strategic planning which serves the overall strategic goal of the enterprise.As a result,human resource management will play an important role in the development of China’s pharmaceutical industry.

Comparative Analysis of Profit Model of Typical Pharmaceutical O2O Enterprises in China

Objective To study the profit model of Chinese pharmaceutical O2O enterprises.Methods A case study of three typical pharmaceutical O2O enterprises was conducted,and their profit models were compared.Results and Conclusion The pharmaceutical O2O enterprises in China are divided into three categories according to the profit models.It is found that the current pharmaceutical O2O enterprises have problems such as simple profit model and low corporate profits.Based on these problems,it is recommended that relevant enterprises develop various business models to increase profit channels.Besides,they should establish and improve internal cost control systems.

Research on the Status Quo and Countermeasures of Human Resource Management Outsourcing in China’s Pharmaceutical Enterprises

Objective To explore the current situation of human resource management outsourcing in China’s pharmaceutical enterprises,and to put forward some suggestions for enterprises and the government.Methods The current situation of human resource management outsourcing in China’s pharmaceutical enterprises was analyzed through the method of literature research.Results and Conclusion At present,the status of human resource management outsourcing in China’s pharmaceutical companies is that the level of human resource outsourcing companies is not high,and there are no relevant industry norms and laws.The information asymmetry between pharmaceutical enterprises and outsourcing companies results in adverse selection and moral hazard.Besides,the different culture of pharmaceutical enterprises and outsourcing companies leads to inefficient communication between enterprises and employee.To solve these problems,the government should promote and improve industry norms and laws to regulate the market.In addition,enterprises should clarify the motivation for outsourcing and make good decision on the outsourcing content.Meanwhile,enterprises should strengthen communication with employees to eliminate employees’concerns.

The Development and Experience of American Pharmaceutical Industry Associations and Its Enlightenment to China

Objective To study the development history and current situation of pharmaceutical industry associations in the United State and to provide reference for China’s pharmaceutical industry associations.Methods Literature research and comparative study were used to investigate the development history and current situation of pharmaceutical associations in the United States.Then,their characteristics and experiences were summarized.Some countermeasures and suggestions were put forward for the existing problems of pharmaceutical associations in China.Results and Conclusion The institutional environment of pharmaceutical associations in the United States is relatively good,reflecting the characteristics of emphasizing process management and neglecting entrance management with and the help of public supervision.At the same time,the government advocates market competition by adhering to the market-oriented services for the public.American pharmaceutical industry associations have strong innovation capacity and perfect credit system.Drawing on the experience of pharmaceutical industry associations in the United States,China should strengthen the construction of pharmaceutical industry associations.Firstly,the supervision mechanism should be improved.Secondly,these associations should have good partnerships with the government and offer the public the best services.Finally,the fund-raising mechanism of pharmaceutical industry associations should be optimized to ensure the innovative development of the pharmaceutical industry.

Flow injection chemiluminescence determination of meloxicam using potassium permanganate and formaldehyde system

A simple, rapid and sensitive flow injection chemiluminescence （FI-CL） method has been developed for the determination of meloxicam. The method is based on the CL-emitting reaction between meloxicam and potassium permanganate in a hydrochloric acid medium, enhanced by formaldehyde （HCHO）. Under optimum conditions, calibration curve over the range of 1.0-20.0μg/mL was obtained. The proposed method was successfully applied to the determination of meloxicam in capsules with no evi- dence of interference from common excipients. The detection limit of this method was 25.6 ng/mL. The relative standard deviation was 2.1% for 10.0 μg/mL meloxicam. The sample throughput was found to be 120 samples/h.

Advances in Medical Applications of Additive Manufacturing

In the past few decades,additive manufacturing(AM)has been developed and applied as a cost-effective and versatile technique for the fabrication of geometrically complex objects in the medical industry.In this review,we discuss current advances of AM in medical applications for the generation of pharmaceuticals,medical implants,and medical devices.Oral and transdermal drugs can be fabricated by a variety of AM technologies.Different types of hard and soft clinical implants have also been realized by AM,with the goal of producing tissue-engineered constructs.In addition,medical devices used for diagnostics and treatment of various pathological conditions have been developed.The growing body of research on AM reveals its great potential in medical applications.The goal of this review is to highlight the usefulness and elucidate the current limitations of AM applications in the medical field.

Chemiluminescence Determination of Benzoic Acid Using A Solid-Phase Verdigris Reactor

A new chemiluminescence flow system has been developed for sequential determina-tion of benzoic acid based on the reaction of the compound with copper carbonate entrapped in a solid-phase reactor. It was found that the unsaturated complex of Cu(II) and benzoic acid (1:1) has strong catalytic effect on the luminol-H2O2 chemiluminescence reaction. The calibration graph is linear over the range of 0.025 ~ 60 g/mL of benzoic acid, with a relative standard deviation of less than 3.0 %, and the detection limit is 0.01礸穖L-1. The proposed method was applied to the determination of benzoic acid content in different pharmaceutical formulations.

Qualitative and semi-quantitative analysis of health-care pharmaceutical products using laser-induced breakdown spectroscopy

Laser-induced breakdown spectroscopy(LIBS) is a sensitive optical technique that is capable of rapid multi-elemental analysis. The development of this technique for elemental analysis of pharmaceutical products may eventually revolutionize the field of human health. Under normal circumstances, the elemental analysis of pharmaceutical products based on chemical methods is time-consuming and complicated. In this investigation, the principal aim is to develop an LIBS-based methodology for elemental analysis of pharmaceutical products. This LIBS technique was utilized for qualitative as well as quantitative analysis of the elements present in Ca-based tablets. All the elements present in the tablets were detected and their percentage compositions were verified in a single shot, using the proposed instrument. These elements(e.g., Ca, Mg, Fe, Zn, and others) were identified by the wavelengths of their spectral lines, which were verified using the NIST database. The approximate amount of each element was determined based on their observed peaks and the result was in exact agreement with the content specification. The determination of the composition of prescription drug for patients is highly important in numerous circumstances. For example, the exploitation of LIBS may facilitate elemental decomposition of medicines to determine the accuracy of the stated composition information. Moreover, the approach can provide element-specific, meaningful, and accurate information related to pharmaceutical products.

信息技术在医院药学教学中的作用

我国医院药学已经进入药学服务（pharmaceutical care）阶段,其核心就是以＂一切以病人为中心＂。这就需要药师对药学信息进行综合管理和处理,为患者、医务人员提供全面、即时的用药指导、医疗决策等相关药学信息产品。可以说,提供全程化的药学服务已成为医院药学发展进步的必然趋势,而药学信息服务则是全程化药学服务的精髓,是医院药学存在和发展的基础。

上海药物研发行业职业健康管理现状与改进策略

目的 了解上海药物研发行业职业健康管理现状及面临的挑战,为制订行业职业健康管理策略,促进行业健康发展提供参考。方法 采用问卷调查法对上海48家药物研发公司的职业健康风险、管理现状及存在的问题进行梳理,采用现场调研法对5家代表性公司实地了解行业职业危害防护和新业态的管理需求,探讨可行的解决方案。结果 问卷调查结果显示半数以上的药物研发公司从事小分子药物和抗肿瘤药物研发,面临着研发试剂、研发中的药物、病原微生物和实验动物等多重健康风险。职业病防护设施“三同时”工作完成率为43.8%,职业病危害因素检测和职业健康监护的开展率分别为89.6%和79.2%。现场调研发现药物研发行业的建筑通风、职业危害防护以及新业态的职业健康管理面临挑战。结论 随着药物研发行业的快速发展,潜在职业健康风险不容忽视,职业危害防护和管理工作亟待细化和完善。

Clinical Application and Pharmaceutical Values of Levant Cotton Root

Levant cotton root is a folk traditional herb with a long history in China. This article gave a brief introduction on recent research work related to main com- position, pharmacologic effect and clinical application of levant cotton root and pro- posed existing problems and countermeasures for pharmaceutical industrialization.